Tetraphase Pharmaceuticals (TTPH) PT Raised to $45 at Guggenheim
Tweet Send to a Friend
Guggenheim analyst Louise Chen reiterated a Buy rating and boosted her price target on Tetraphase Pharmaceuticals (NASDAQ: TTPH) to $45.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
